$STSA "Mitzuho noted that the company said there were statistically significant benefits seen with both doses at the three hour time point and at later time points. 'However, given the product is intended to be used to treat ACUTE migraines, it is not clear to us how much value that delayed impact would have for patients,' Mizuho Securities said.."
  • 1